Vamorolone approved in the US

The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...

World Muscle Society awards 2023 DRF prize

The World Muscle Society has once again awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 28th congress in Charleston, South Carolina, USA, in October 2023 was...

Catalysts Pharmaceuticals to distribute vamorolone in North America

Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals...

Psychosocial project now under way with DRF funding

28th February is Rare Disease Day. Duchenne muscular dystrophy may be a rare disease, but it can bring with it challenges which are all too familiar. There is an increased risk of mental health, emotional and behavioural needs in Duchenne muscular dystrophy patients,...

Solid completes acquisition of AavantiBio

We are pleased to share that Solid Biosciences has completed its acquisition of gene therapy company AavantiBio, to create a genetic medicine company focused on neuromuscular and cardiac rare disease, with a continued, strong focus on Duchenne. At this pivotal moment...

Parents urged to read new cardiac recommendations for Duchenne

DMD Care UK’s new cardiac care recommendations have been published in the BMJ Open Heart journal. All Duchenne parents and caregivers are being urged to read the new guidance and share with their networks, as protecting the heart early is crucial to preventing...